The Phase 3 program is expected to further characterize the optimal escalation protocol for potential regulatory submission
There is no clinical evidence that taking the injection at a specific time of day reduces gastrointestinal side effects, but personal experience and preference may guide this choice
Studies and real-world use suggest that the injectable formulation can offer a more predictable and manageable side effect profile for most patients
Sisley S, Gutierrez-Aguilar R, Scott M, DAlessio DA, Sandoval DA, Seeley RJ (2014)
The necessity of daily shots and potential side effects such as nausea at the start of treatment can influence how well patients stick to their regimen and their overall contentment with the therapy
Gastrointestinal complications alleged in GLP-1 litigation include: These allegations can overlap with other health conditions, including high blood pressure and other comorbidities that may complicate diagnosis and causation analysis